Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 193 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Triostat Clear all

Conditions: Parenting, Adolescent - Emotional Problem, Mental Disorder in Adolescence
Interventions: Parenting Wisely Residential Treatment (PWRT), TAU; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 11 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prostate Cancer, Erectile Dysfunction, Urinary Incontinence
Interventions: Yoga, Usual Care; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions: fluorouracil, oxaliplatin, radiation therapy, leucovorin calcium, therapeutic conventional surgery; Drug · Radiation · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: TAK-831 T2, TAK-831 T3; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Thyroid Neoplasm
Interventions: Valproic Acid, Liothyronine Sodium; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Inflammatory Bowel Diseases
Interventions: Biofeedback Enhanced Treatment; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Fibromyalgia
Interventions: T3; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Major Depression
Interventions: Triiodothyronine, Placebo, Sertraline; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Schizophrenia
Interventions: rTMS with fMRI-based targeting, rTMS with landmark-based targeting; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 60 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Caregivers
Interventions: webcasts, Assessments, Usual care; Other · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Segmental and Somatic Dysfunction of Other Regions (M99.09)
Interventions: OMT; Other
Lead sponsor: New York Institute of Technology; Other
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Jonesboro, Arkansas

Conditions: Animal-Human Bonding, Learning Problem, Child Development
Interventions: Human-Animal Interactions; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Brentwood, Tennessee

Conditions: Healthy
Interventions: LY4268989; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Post-Mastectomy Chronic Pain Syndrome
Interventions: Regenerative Peripheral Nerve Interface; Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer
Interventions: therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy; Biological · Drug · Genetic + 3 more
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Tampa, Florida • Omaha, Nebraska

Conditions: Rectal Cancer
Interventions: Capecitabine, Irinotecan, EUS, Neoadjuvant Chemotherapy, Preoperative Radiation, Surgery, Adjuvant Chemotherapy; Drug · Procedure
Lead sponsor: Gabi Chiorean, MD; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 9
States / cities: Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more

Conditions: Cervical Cancer, Hiv
Interventions: Retention in cervical cancer care intervention; Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: IMRT, 3D; Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Neoplasm
Interventions: HydroMARK Plus Clip; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: New Onset Atrial Fibrillation, Anesthesia, Local, Cardiac Disease
Interventions: Ropivacaine 0.2% Injectable Solution; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Insulin Resistance, Diabetes Mellitus, Abnormal Glucose Metabolism
Interventions: Liothyronine; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: PTSD, Post Traumatic Stress Disorder, Traumatic Brain Injury
Interventions: Non-Trauma Treatment for TBI and PTSD; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Fort Hood, Texas

Conditions: Rectal Cancer
Interventions: Standard of care chemotherapy with the change for avoidance of extensive surgery; Procedure
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 95 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Barrett Esophagus, Esophageal Adenocarcinoma
Interventions: Cancer Screening, Computer-Assisted Intervention, Endoscopic Procedure, Health Risk Assessment, Navigation, Questionnaire Administration; Other · Procedure · Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1,010 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Scottsdale, Arizona • Rochester, Minnesota • Eau Claire, Wisconsin

Search by objective public record fields.

Optimizing Residential Treatment Gains for Adolescents

A Yoga Program for Patients Undergoing Prostate Cancer Surgery

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer

A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin

Heart Rate Variability and Inflammatory Bowel Disease

Study of T3 for the Treatment of Fibromyalgia

Thyroid Medication and Antidepressants for Treating Major Depression

Transcranial Magnetic Stimulation for the Treatment of Auditory Hallucinations in Schizophrenia

Care For The Cancer Caregiver: A Meaning-Based Workshop To Help Manage Caregiver Burden

Effects of Osteopathic Manipulative Treatment of Fascial Restrictions on Body Awareness, Mood, and Proprioception

Human-Animal Interactions to Improve Reading for Children With Learning Differences

A Study of LY4268989 (MORF 057) in Healthy Participants

Surgical Treatment of Post-surgical Mastectomy Pain Utilizing the Regenerative Peripheral Nerve Interface

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer

Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade Among Women With HIV in South Africa: Part 2

A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer

Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction

Paravertebral Block to Reduce the Incidence of New Onset Atrial Fibrillation After Cardiac Surgery

Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations

Non-Trauma Intervention to Treat PTSD for Veterans and Service Members Suffering From a TBI

Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders

Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial